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A b s t r A c t
Arrhythmogenic right ventricular cardiomyopathy/ dysplasia (ARVC/D), mostly af-
fecting young/middle-aged individuals, poses a significant risk of malignant ventricu-
lar arrhythmias (VAs) and subsequent sudden cardiac death (SCD). Antiarrhythmic 
agents (AAA) provide insufficient arrhythmia suppression and prevention and can be 
proarrhythmic. Thus, the implantable cardioverter defibrillator (ICD) is considered 
the first-line treatment, especially in patients with secondary prevention indication. 
Nevertheless, catheter ablation is an additional therapy to the ICD which has proved 
its efficacy in primary and secondary prevention of fatal arrhythmias and sudden car-
diac death. The superiority of the combined endo- and epicardial VT ablation in this 
population is clear since the ARVC/D substrate has been shown to be mostly epicar-
dial. Due to progressive nature of ARVC/D, ablation seems to be a useful tool for the 
patients who experience recurrent VT episodes or electrical storms.
I N t r O D U c t I O N
Arrhythmogenic right ventricular cardiomyopathy/ dysplasia (ARVC/D) poses a 
significant risk of malignant ventricular arrhythmias (VAs) and subsequent sudden 
cardiac death (SCD).1 On top of the fact that young/ middle-aged individuals are mostly 
affected, imperative issues emerge regarding primary and secondary prevention of 
catastrophic ventricular arrhythmogenesis.1 Antiarrhythmic agents (AAA) provide 
insufficient arrhythmia suppression and prevention and can be proarrhythmic.2 In this 
context, implantable cardioverters-defibrillators (ICDs) are considered the first-line 
treatment, especially in patients with an indication for secondary prevention of SCD.3 
However, a substantial amount of discrepancy remains as to which patients without 
documented VAs are optimal candidates for ICD implantation, based on arrhythmic 
risk stratification schemes. Prospective studies in patients with implanted ICDs accord-
ing to the arrhythmic risk factors let somebody see that only a minority of them receive 
appropriate ICD intervention, while significant proportions present with inappropriate 
ICD interventions and/or device-related complications.4
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In all cases, what ICDs are incapable of is prevention of 
arrhythmias occurrence and, of more importance, modification 
or elimination of the arrhythmogenic substrate. Radiofrequen-
cy catheter ablation (RFA) effectively modifies and/or elimi-
nates abnormal arrhythmogenic substrate. In post-infarction 
patients with mainly subendocardial scars and slow conduction 
areas, RFA is an established therapy for malignant ventricular 
arrhythmias.5 Regarding ARVC/D, though, the abnormal 
substrate appears not to be confined to the subendocardium. 
In fact, recent research work has demonstrated the presence 
of scarring, creating re-entry circuits due to slow conduction 
and unidirectional block promoting thus arrhythmogenesis in 
the epicardium.6 State-of-the-art ablation procedures include 
epicardial electroanatomical mapping (EAM) and ablation, 
not only after failure of endocardial ablation, but even as 
first-line approach.7 The combined use of endocardial and 
epicardial ablation has given more than encouraging results 
in patients presenting with VAs and has raised significantly 
rates of arrhythmia-free survival.7,8
E l E c t r O A N A t O m I c  A N D 
E l E c t r O p H y s I O l O g I c  s U b s t r A t E
ARVC/D is a genetically determined cardiomyopathy 
which typically affects the right ventricle (RV); involvement 
of the left ventricle (LV) is now commonly recognized, espe-
cially in the late stages of the disease, while recent data sug-
gests that it may in fact precede the onset of significant RV 
dysfunction.9-12 It primarily results from defective desmosomal 
proteins with the subsequent myocardial degeneration and 
death causing replacement of right and/or ventricular myo-
cardium by fibrofatty tissue.9,13,14 Along with RV enlargement 
and dysfunction, RV aneurysms are typical of ARVC/D and 
are detected in the so-called “triangle of dysplasia”, i.e., RV 
outflow tract, apex, and outflow tract.15 Sites of left ventricle 
(LV) involvement, demonstrated by late enhancement cardiac 
magnetic resonance (LECMR), include more often the infe-
rolateral wall, inferior wall-septal junction, inferior wall and 
septum.12 Through functional myocardial tissue degeneration 
and replacement, the two principal prerequisites for reentry 
are met. The intercellular coupling is deranged leading to 
slower impulse conduction and, secondly, areas of anatomic 
and/or functional unidirectional block are created.
High-density electroanatomic mapping (EAM) has been 
used to characterize the electrical correlates of arrhythmogenic 
substrate in ARVC/D. Bipolar RV endocardium signals are 
considered normal if they display up to 3 deflections from 
baseline, with amplitude of more than 1.5 mV, while dense 
scar is demonstrated by amplitudes less than 0.5 mV.16,17 Re-
garding the epicardium, an amplitude in the bipolar setting of 
more than 1.0 mV is considered normal, which corresponds to 
95% of the signals recorded at a distance at least 1 cm from 
the defined large vessel coronary vasculature.18 In patients 
with minimal or moderate endocardial disease involvement, 
the extent of epicardial scar can also be reliably evidenced 
with application of endocardial unipolar mapping, using a 
cutoff of <5.5 mV for normal endocardial unipolar voltage.19 
The areas of endocardial electroanatomic scar, as defined by 
studies conducted to seek endocardial ventricular tachycardia 
(VT) ablation efficacy, extend from the tricuspid or pulmonary 
valve to the RV free wall, while the RV apex seems to be ex-
cluded.20,21 High-density EAM in the epicardium has revealed 
that low-voltage epicardial areas correspond well to endocar-
dial anatomical ones but extend further over the surface of the 
RV.7,22 In ARVC/D the RV epicardium activation is delayed 
and independent of the underlying endocardium activation. In 
particular, compartmentalization of the epicardium from the 
endocardium and VT circuits defined only to the epicardium 
are created, explaining the low rates of success and high rates 
of VT recurrence when an endocardial-only ablative strategy 
is applied.6 Of importance, the existence of scarring and low 
voltage areas does not dogmatically predict arrhythmic events. 
As Santangeli et al23 report, in primary prevention patients 
prospectively followed after ICD implantation, fragmented 
and late activation potentials recorded within the scar and not 
RV electroanatomic scar itself, were linked with subsequent 
malignant arrhythmogenesis.
r I s K  s t r A t I f I c A t I O N  
A N D  m A N A g E m E N t
The majority of affected individuals develop symptoms 
during the second to fourth decade of life. The latter, espe-
cially during the early “concealed” stage of the disease, where 
gross changes in the cardiac muscle architecture are difficult 
or impossible to define, include mainly malignant ventricular 
arrhythmias, syncope and in some cases SCD.10 Survivors of 
cardiac arrest present mainly with sustained ventricular tachy-
cardia (VT) or ventricular fibrillation (VF), receive an ICD in 
the context of secondary prevention and have rates of VT/VF 
incidence of up to 70% during follow up.24,25
The subgroup of patients without documented VAs is 
typically stratified according to arrhythmic risk factors. Such 
factors include induction of VT during an electrophysiology 
study (EPS), detection of non-sustained VT on noninvasive 
monitoring, male gender, severe RV dilation, extensive RV 
involvement, young age at presentation (less than 5 years), 
LV involvement, prior cardiac arrest, unexplained syncope 
and genotypes of ARVD/C associated with a high risk for 
SCD.3 The John Hopkins registry reported 48% appropri-
ate ICD interventions during follow-up. Inducibility at EPS, 
non-sustained VT and high burden of ventricular ectopy were 
independent strong predictors of appropriate ICD therapy.26 
On the other hand, Corrado et al report a lower, albeit signifi-
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cant, percentage of 24%. They define syncope as an important 
predictor of life-saving ICD intervention, while programmed 
ventricular stimulation seems to have a low predictive accuracy 
for appropriate ICD intervention.4
c A t H E t E r  A b l A t I O N
A significant proportion of appropriate ICD therapies is 
delivered due to episodes of electrical storm.27,28 The afore-
mentioned data sufficiently highlight the urge for therapies 
that move one step forward in the field of arrhythmogenic 
substrate modification/elimination rather than malignant VAs 
termination. General recommendations regarding catheter 
ablation indications in patients with structural heart disease 
are summarized in Table 1.29
In patients with ischemic cardiomyopathy (ICM), RFA has 
been shown to be more efficacious compared to individuals 
with non-ischemic cardiomyopathies. In the field of ARVC/D 
the results from the studies carried out in patients with VTs 
are controversial. Although there are no large clinical trials 
in this population, the results are not encouraging regarding 
RFA. As in ICM, two end-points have been proposed indicat-
ing acute success, either non-inducibility of the clinical VT or 
of any inducible VTs. The first clinical studies during late 90’s 
enrolled only a few patients and the procedures were carried 
out conventionally, typically with pace- and entrainment map-
ping techniques, without using EAM systems. One of them 
was conducted by Harrada et al, who enrolled 7 patients using 
entrainment endocardial mapping to identify the reentrant 
circuit. They demonstrated that RFA was most successful at 
narrow isthmuses of the re-entry circuits, proving that in this 
population re-entry predominates as VT generating mecha-
nism.30 Although nowadays RFA is the commonly used tech-
nique, in the early 1990s direct current (DC) fulguration was 
also widely used. According to Fontaine et al, who compared 
the efficacy of these two techniques in patients with ARVC/D, 
the effectiveness/efficacy of RFA alone was about 40%, while 
DC fulguration was successful after RFA failure. In these 50 
patients, the success rate during the follow up was 81% for DC 
ablation and 93% for combined DC and RFA.31
Moreover, in the past years a non-contact mapping tech-
nique with a balloon catheter was introduced in the clinical 
practice of VT ablation. This technique using the far-field 
unipolar electrograms obtained from the endocardium allows 
the creation of an activation map, although sometimes it is not 
possible to detect the low voltage electrograms. In patients with 
ARVC/D, results seem to be promising, since in a group of 32 
subjects acute success was achieved in 84.4% of them and at 
the end of follow up 81.3% were free of VT.32
Table 2 summarizes the results from the most important 
published clinical trials for VT ablation in patients with 
ARVC/D. Due to different ablation techniques, endpoints 
used and the overall post ablation management of the patients, 
regarding the use of AAA, ICDs and follow up duration, there 
is an obvious variability among these results. Most of the 
studies published after 2000 included patients with implanted 
ICDs, either before inclusion or during the study, since its ef-
fectiveness is undeniable. A large observational study showed 
that about half of the patients with ARVC/D had at least one 
episode of ventricular tachyarrhythmia that required ICD 
therapy over a mean follow-up period of 3.3 years, and 24% 
experienced potentially fatal arrhythmias as ventricular fibril-
lation or flutter, suggesting thus the beneficial effect of the 
ICDs.33 Ablation in these patients seems to reduce the number 
of VA episodes especially when it is performed both endocardi-
ally and epicardially. Recently published data showed that, in 
a population of 49 patients, 52.2% were free of VAs or ICD 
therapy during a 3-year follow up after endocardial ablation 
compared to 84.6% after combined endo- and epi-cardial abla-
tion (P=0.029). Moreover, patients with frequent premature 
ventricular contractions after ablation were more likely to have 
VA recurrence or ICD therapy (P <0.001).7 
Although the acute success rate after VT ablation seems 
to be satisfactory in patients using an endocardium-confined 
approach, late recurrence remains a principal drawback. Re-
cent advances in EAM and catheter ablation technology have 
contributed to the better understanding of the VT substrate in 
ARVC/D. Electroanatomical mapping data were compared 
between patients with ARVC/D and patients without structural 
heart disease who both underwent endocardial and epicardial 
mapping (Fig. 1). The identified scar area was larger in the 
epicardium compared to the endocardium (P=0.04). Addition-
ally, ARVC/D patients had longer epicardial and endocardial 
activation times compared to controls. Specifically, in these 
patients a more than four-fold greater delay between the last 
tAblE 1. Indications for catheter ablation of ventricular tachycardia associated with structural heart disease29
1 Recurrent symptomatic sustained monomorphic VT (SMVT), including VT terminated by an ICD despite AAA or when AAA are 
not tolerated or not desired
2 Control of incessant SMVT or VT storm that is not due to a transient reversible cause
3 Recurrent sustained polymorphic VT and VF refractory to AAA when there is suspected trigger that can be targeted for ablation
AAA = antiarrhythmic agents; ICD = implantable cardioverter defibrillator; VF = ventricular fibrillation; VT = ventricular tachycardia
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recorded endocardial activation and the latest epicardial right 
ventricular sites was demonstrated, simultaneously with the 
presence of late epicardial isolated potentials. On the contrary, 
the control patients had the latest epicardial activation within 
20 ms after the latest RV endocardial activation.6 The same 
activation template became clear after direct surgical map-
ping in 4 patients with ARVC/D, which showed the earliest 
activation points in the epicardium.34 Garcia et al performed 
epicardial ablation in 12 out of 13 patients with failed endo-
cardial ablation and after a mean follow up of 18±13 months, 
77% of the patients were free of sustained VT. The authors 
noted that the epicardial VT origin site was in proximity to the 
tricuspid annulus at the acute angle of the RV and this epicar-
dial successful ablation region was in some of the patients >1 
cm away from the previous failed endocardial ablation site.35 
More recently, Bai et al7 compared the long-term results by 
using endocardium-confined ablation versus endo-epicardial 
substrate-based ablation in patients with ARVC/D, reporting 
a rate of freedom from any VT of 52.2% and 84.6%, respec-
tively. The existence of more than 10 premature ventricular 
complexes per minute was associated with more high percent-
age of VT recurrence. Added to the latter, newer data confirm 
the superiority of epicardial ablation in this population. In 
87 patients from 80 different centers, those who underwent 
epicardial ablation were free from VT recurrence by 64% 
and 45% at 1 and 5 years of follow up, respectively, which was 
significantly larger compared to endocardial RFA (P=0.021).8 
The incidence of major complications during the pericardial 
procedures was about 7.7%, similar to those reported in the 
literature about all VT categories epicardial ablation. Epicar-
dial ablation seems also to be efficient in pediatric patients 
with ARVC. Pokushalov et al36 showed that in 17 pediatric 
patients with recurrent VTs due to failed prior endocardial 
ablation or AAA inefficacy, epicardial VT ablation resulted 
to non-inducibility of the VT in most of them (16 of 17 pts). 
After a follow-up period of 26±15 months without receiving 
AAA, 70.6% of them were free of arrhythmia episodes. 
c O N c l U s I O N
In patients with ARVC/D, catheter ablation is an ad-
fIgUrE 1. Endocardial (ENDO) and epicardial (EPI) voltage maps with the CARTO-3 system of a patient submitted for ventricular 
tachycardia ablation and diagnosis of ARVD in right lateral view. A low-voltage area is present in the epicardial surface. The epi-
cardial scar is wider than the endocardial. Normal myocardium (>1.5 mV) is coded in purple, scar (<0.5 mV) is coded in red. Red 
dots: radiofrequency applications.
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ditional therapy to the ICD which has proved its efficacy in 
primary and secondary prevention of fatal arrhythmias and 
sudden cardiac death. The superiority of the combined endo- 
and epicardial VT ablation in this population is clear, since the 
ARVC/D substrate has been shown to be mostly epicardial. 
Due to progressive nature of ARVC/D, ablation seems to be 
a useful tool for the patients who experience recurrent VT 
episodes or electrical storms. Using the new three-dimensional 
(3D) EAM mapping systems we are able to modify the ar-
rhythmogenic endocardial and/or epicardial substrate and to 
abolish the re-entrant circuits which are responsible for the 
genesis of these macroreentry or focal tachycardias. Larger 
well organized multicenter trials are required to investigate 
the long-term effect favorable or not of the ablation therapy 
in these patients using the current endocardial and epicardial 
approach.
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